Arcturus Appoints John Markels, Ph.D. to its Board of Directors
13 Dezembro 2022 - 10:30AM
Business Wire
Dr. Markels, accomplished and experienced
industry executive, most recently President of Global Vaccines at
Merck, to provide strategic oversight to the Company’s vaccine
franchise
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that is has appointed John Markels,
Ph.D., an accomplished pharmaceutical executive with over 35 years
of industry experience, to its Board of Directors. As part of this
role, Dr. Markels will provide strategic oversight to the Company’s
vaccine franchise and manufacturing processes.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221213005428/en/
John Markels, Ph.D. (Photo: Business
Wire)
“We are very pleased to welcome Dr. John Markels to the Arcturus
Board,” said Joseph Payne, President & CEO of Arcturus. “John
is an accomplished industry leader with exceptional vaccine and
manufacturing expertise gained from a prolific career with Merck.
John’s experience will be particularly valuable as we advance our
pipeline of mRNA therapeutics and work alongside our strategic
collaborator, CSL Seqirus, to develop and commercialize novel
self-amplifying mRNA vaccines.”
“Arcturus has pioneered a differentiated mRNA technology
platform that is well positioned to lead a new class of highly
effective vaccines for pathogens of global concern, as well as
innovative medicines for certain important diseases. I look forward
to working closely with the team to support the manufacturing and
delivery of next generation mRNA medicines and vaccines globally,”
said John Markels, Ph.D., Director at Arcturus.
Dr. Markels Biography
Dr. Markels has over 35 years of leadership experience in the
pharmaceutical industry at Merck & Co., Inc., with a deep
background in manufacturing, development, and technology transfer
as well as global commercial, policy, and organizational
development. Dr. Markels serves on the Board of Sangamo
Therapeutics and chairs and serves on the advisory boards for the
University of California, Berkeley College of Chemistry and
University of Delaware Department of Chemical and Biomolecular
Engineering, respectively. Dr. Markels retired from Merck in March
2022, most recently as President of Global Vaccines, a large and
growing business where he led an integrated team dedicated to
discovery and development, supply and access, and global marketing
and long-term strategy for the vaccines portfolio. Earlier roles at
Merck included President, Latin America, as well as a long career
in senior leadership positions in major regions worldwide in
manufacturing technology, operations, supply chain and strategy.
Dr. Markels has worked in every region of the world and lived in
the U.S., Latin America and Europe. He received his Ph.D. in
Chemical Engineering from the University of California, Berkeley
and his B.S. in Chemical Engineering from the University of
Delaware.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic and vaccine candidates includes mRNA vaccine programs
for SARS-CoV-2 (COVID-19) and Influenza, and other programs to
potentially treat ornithine transcarbamylase (OTC) deficiency, and
cystic fibrosis, along with partnered programs including glycogen
storage disease type III, and hepatitis B virus. Arcturus’
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, circular RNA, antisense RNA, self-amplifying RNA,
DNA, and gene editing therapeutics. Arcturus’ technologies are
covered by its extensive patent portfolio (patents and patent
applications issued in the U.S., Europe, Japan, China and other
countries). For more information, visit www.ArcturusRx.com. In
addition, please connect with us on Twitter and LinkedIn.
Trademark Acknowledgements
The Arcturus logo and other trademarks of Arcturus appearing in
this announcement, including LUNAR® and STARR™, are the property of
Arcturus. All other trademarks, services marks, and trade names in
this announcement are the property of their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221213005428/en/
Arcturus Therapeutics Neda Safarzadeh VP, Head of
IR/PR/Marketing 858-900-2682 IR@ArcturusRx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024